The monoglutamate form can stimulate glioma cell proliferation by activating MAPK and PI3K/AKT pathways (Schneider and Ryan, 2006; Oleinik et al., 2014; Robert and Sontheimer, 2014). Here, AKT1 is linked to central nervous system cancer.